MedWire News -- Disabling strokes and severe bleeds are each associated with an increased risk for mortality in patients receiving antithrombotic therapy for atrial fibrillation (AF), a new analysis of the ACTIVE-W trial suggests.
MedWire News -- Disabling strokes and severe bleeds are each associated with an increased risk for mortality in patients receiving antithrombotic therapy for atrial fibrillation (AF), a new analysis of the ACTIVE-W trial suggests.